TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
10.1016/j.physbeh.2008.10.019 96 MaddenS.CarrazanaE.RabinowiczA
Metabolism: Clinical and Experimental 2013:11991205
At such times, it may be necessary to add insulin in combination with glimepiride or even use insulin monotherapy
consider concentration per vial, required dosage per treatment, minimum order quantities (MOQ), bulk pricing tiers, shipping costs, and potential wastage
